Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG003 in Wet AMD
NCT00414206Phase 2Terminated
- Sponsor
- CoMentis, Inc.
- Start
- Mar 2007
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of mecamylamine in neovascular age-related macular degeneration (NVAMD), sponsored by CoMentis, Inc.. Started Mar 2007; status: terminated.
02
Drugs
mecamylamine
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00414206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00414206.